Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | F2R | P25116 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376847 | 0.93 | MIF (0.49) | MIFMEN1KMT2ADUSP3PTPN11 | |
| SCHEMBL17165027 | 0.79 | ALDH1A1 (0.41) | MIFMEN1KMT2ADUSP3PTPN11 | |
| SCHEMBL20237367 | 0.79 | MIF (0.46) | MIFMEN1KMT2ADUSP3PTPN11 | |
| SCHEMBL9694390 | 0.77 | F2R (0.39) | ALDH1A1MAPK1HTTPOLBMAPT | |
| SCHEMBL17156089 | 0.76 | MIF (0.49) | MIFMEN1KMT2ADUSP3PTPN11 | |
| SCHEMBL17156172 | 0.76 | MIF (0.46) | MIFMEN1KMT2ADUSP3PTPN11 | |
| SCHEMBL11132050 | 0.74 | F2R (0.51) | MEN1KMT2AALDH1A1MAPK1POLB | |
| SCHEMBL18421326 | 0.74 | MIF (0.50) | MIFMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL2352374 | 0.72 | CYP1A2 (0.50) | MEN1KMT2AALDH1A1MAPK1HTT | |
| SCHEMBL30552341 | 0.72 | CYP1A2 (0.50) | MEN1KMT2AALDH1A1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160732-B2 | MIF inhibitors | MIFCARE (FR) | 2018-12-25 | — | — | US | claimed |
| EP-2929882-B1 | MIF inhibitors | MIFCARE (FR) | 2018-06-13 | — | — | EP | claimed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | claimed |
| WO-2015155358-A1 | MIF INHIBITORS | MIFCARE (FR) | 2015-10-15 | — | — | WO | claimed |
| EP-2929882-A1 | MIF inhibitors | Mifcare (FR) | 2015-10-14 | — | — | EP | claimed |
| US-10160732-B2 | MIF inhibitors | MIFCARE (FR) | 2018-12-25 | — | — | US | disclosed |
| EP-2929882-B1 | MIF inhibitors | MIFCARE (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-20170029387-A1 | MIF INHIBITORS | APAXEN (BE) | 2017-02-02 | — | — | US | disclosed |
| WO-2015155358-A1 | MIF INHIBITORS | MIFCARE (FR) | 2015-10-15 | — | — | WO | disclosed |
| EP-2929882-A1 | MIF inhibitors | Mifcare (FR) | 2015-10-14 | — | — | EP | disclosed |
| EP-0330613-B1 | COMPOSITIONS AND METHOD FOR INHIBITING CORROSION | CIBA-GEIGY AG (CH) | 1993-08-18 | — | — | EP | disclosed |
| US-5190723-A | Phenol substituted with thioether compound | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0330613-A2 | Compositions and method for inhibiting corrosion | CIBA-GEIGY AG (CH) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160732-B2 | MIF inhibitors | MIF, MSR1, MMP12 | MIF 1/4885MEN1 2049/4885KMT2A 4284/4885 |
| US-20170029387-A1 | MIF INHIBITORS | MIF, MSR1, MMP12 | MIF 1/4885MEN1 2049/4885KMT2A 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.